A new protein which will help scientists understand why nerve cells die in people with Alzheimer's disease has been designed in a University of Sussex laboratory. In people with Alzheimer's, Amyloid-beta (Abeta) proteins stick together to make amyloid fibrils which form clumps between neurons in the brain. It is believed that the build-up of these clumps causes brain cells to die, leading to the cognitive decline in patients suffering from the disease.
It is not known why this particular protein's "stickiness" causes cells to die and scientists have been unable to properly test whether the sticky clumps of Abeta proteins have different effects, compared with individual proteins that are not stuck together.
Now University of Sussex scientists
The new protein will be an essential laboratory tool for researchers working to understand the causes and role of Abeta plays in Alzheimer's disease. The scientists who designed it are now working closely with the Sussex Innovation Centre to research commercial opportunities for the protein.
"Understanding how the brain protein Abeta causes nerve cell death in Alzheimer's patients is key if we are to find a cure for this disease," said Dr Karen Marshall, who led the study. "Our study clearly shows that the aggregation of Abeta into bigger species is critical in its ability to kill cells. Stopping the protein aggregating in people with Alzheimer's could slow down the progression symptoms of the disease. We hope to work towards finding a strategy to do this in the lab and reverse the damaging effects of toxic Abeta."
Professor Louise Serpell, a senior author on the study and co-director of the University of Sussex's Dementia Research Group, said: "This is a really exciting new tool that will contribute to research to uncover the causes for Alzheimer's disease, and enable tangible progress to be made towards finding targets for therapy."
"It's a really exciting development," agreed Peter Lane, Innovation Support Manager at the Sussex Innovation Centre. "The Centre is thrilled to be working alongside Professor Serpell to make sure the benefits offered by this new laboratory tool are made widely available to the Alzheimer's research community in the very near future."